Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

Pharmacogenomics. 2017 May;18(7):631-638. doi: 10.2217/pgs-2017-0014. Epub 2017 May 4.

Abstract

Aim: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept.

Materials & methods: We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68).

Results: The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months. Besides polymorphisms rs928655 (GBP6) and rs2546890 (IL12B) were associated to response at 6 months.

Conclusions: Nevertheless, these biomarkers should be validated in large-scale studies before its implementation in clinical practice.

Keywords: etanercept; pharmacogenetics; psoriasis.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Etanercept / therapeutic use*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Polymorphism, Genetic / genetics*
  • Prospective Studies
  • Psoriasis / drug therapy*
  • Psoriasis / genetics*
  • Severity of Illness Index*
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Etanercept